Edwards Lifesciences (EW) Citi’s 2026 Unplugged MedTech and Life Sciences Access Day summary

Leadership and organizational updates

• Gerrianne Sarte will become Head of Investor Relations in April, bringing extensive MedTech and healthcare experience.

TAVR market dynamics and growth

• TAVR market saw acceleration in late 2024 and 2025, driven by positive clinical trial results and FDA approvals.

• Sequential growth in Q3 2025 was unusual and attributed to EARLY TAVR Trial results and SAPIEN 3 Ultra RESILIA approval.

• Upcoming U.S. NCD and evolving guidelines are expected to further impact TAVR.

Hospital capacity and procedural trends

• Growth is influenced by both increased cath lab capacity and improved scheduling among hospital teams.

• CMS is considering operator requirements in the new NCD to reduce scheduling friction.